

## **Supporting Information**

for

Isolation and characterisation of irinans, androstane-type withanolides from *Physalis peruviana* L.

Annika Stein, Dave Compera, Bianka Karge, Mark Brönstrup and Jakob Franke

Beilstein J. Org. Chem. 2019, 15, 2003-2012. doi:10.3762/bjoc.15.196

NMR, MS, UV and IR spectra of irinan A (2) and irinan B (3).

NMR data of withanolide E (4), withanolide F (5) and perulactone H (6)

- Figure S1. HRESIMS spectrum of 2
- Figure S2. <sup>1</sup>H NMR spectrum of **2** in CDCl<sub>3</sub> at 298.0 K (500 MHz)
- Figure S3. <sup>13</sup>C NMR spectrum of **2** in CDCl<sub>3</sub> at 298.0 K (125 MHz)
- Figure S4. <sup>1</sup>H, <sup>1</sup>H COSY spectrum of **2** in CDCl<sub>3</sub> at 298.0 K (500 MHz)
- Figure S5. HSQC spectrum of 2 in CDCl<sub>3</sub> at 298.0 K (500 MHz; 125 MHz)
- Figure S6. HMBC spectrum of 2 in CDCl<sub>3</sub> at 298.0 K (500 MHz; 125 MHz)
- Figure S7. NOESY spectrum of 2 in CDCl<sub>3</sub> at 298.0 K (500 MHz)
- Figure S8. IR spectrum of 2
- Figure S9. UV-vis spectrum of 2 in MeOH
- Figure S10. HRESIMS spectrum of 3
- Figure S11. <sup>1</sup>H NMR spectrum of **3** in CDCl<sub>3</sub> at 298.0 K (500 MHz)
- Figure S12. <sup>13</sup>C NMR spectrum of **3** in CDCl<sub>3</sub> at 298.0 K (125 MHz)
- Figure S13. <sup>1</sup>H, <sup>1</sup>H COSY spectrum of **3** in CDCl<sub>3</sub> at 298.0 K (500 MHz)
- Figure S14. HSQC spectrum of 3 in CDCl<sub>3</sub> at 298.0 K (500 MHz; 125 MHz)
- Figure S15. HMBC spectrum of **3** in CDCl<sub>3</sub> at 298.0 K (500 MHz; 125 MHz)
- Figure S16. NOESY spectrum of 3 in CDCl<sub>3</sub> at 298.0 K (500 MHz)
- Figure S17. IR spectrum of 3
- Figure S18. UV-vis spectrum of 3 in MeOH
- Figure S19. Origin of an unusual dddddd multiplet.
- Figure S20. Proposed biosynthetic precursors of irinan A (2), B (3) and the previously reported androwithanolide cinedione (8).
- Figure S21. Intrinsic reactivity of 4β-hydroxywithanolide E (1) in oxidative conditions.
- Table S1. <sup>1</sup>H NMR data (CDCl<sub>3</sub>, 400 MHz, 298 K) of withanolide E (**4**), withanolide F (**5**) and perulactone H (**6**) in comparison with literature data (δ in ppm, *J* in Hz).




Figure S1. HRESIMS spectrum of 2.




Figure S2. <sup>1</sup>H NMR spectrum of 2 in CDCl<sub>3</sub> at 298.0 K (500 MHz).




Figure S3. <sup>13</sup>C NMR spectrum of **2** in CDCl<sub>3</sub> at 298.0 K (125 MHz).




Figure S4. <sup>1</sup>H, <sup>1</sup>H COSY spectrum of 2 in CDCl<sub>3</sub> at 298.0 K (500 MHz).





Figure S5. HSQC spectrum of 2 in CDCl<sub>3</sub> at 298.0 K (500 MHz; 125 MHz).



**Figure S6.** HMBC spectrum of **2** in CDCl<sub>3</sub> at 298.0 K (500 MHz; 125 MHz).




Figure S7. NOESY spectrum of 2 in CDCl<sub>3</sub> at 298.0 K (500 MHz).




Figure S8. IR spectrum of 2.




Figure S9. UV-vis spectrum of 2 in MeOH.




Figure S10. HRESIMS spectrum of 3.





Figure S11. <sup>1</sup>H NMR spectrum of 3 in CDCl<sub>3</sub> at 298.0 K (500 MHz).






Figure S13. <sup>1</sup>H-<sup>1</sup>H COSY spectrum of 3 in CDCl<sub>3</sub> at 298.0 K (500 MHz).




Figure S14. HSQC spectrum of 3 in CDCl<sub>3</sub> at 298.0 K (500 MHz; 125 MHz).




Figure S15. HMBC spectrum of 3 in CDCl<sub>3</sub> at 298.0 K (500 MHz; 125 MHz).




Figure S16. NOESY spectrum of 3 in CDCl<sub>3</sub> at 298.0 K (500 MHz).




Figure S17. IR spectrum of 3.





Figure S18. UV-vis spectrum of 3 in MeOH.



**Figure S19.** Origin of an unusual dddddd multiplet. A) Coupling partners (red) of H-4β (blue) in irinan B (3). B) H-4β appears as a dsext (expected for a sextet 1:5:10:10:5:1) in a  $^{1}$ H NMR spectrum (500 MHz, CDCl<sub>3</sub>, 298 K). C) COSY analysis reveals  $^{2}$ *J* coupling to H-4α (21.3 Hz) and five additional correlations (which must be  $\approx$ 2.8 Hz to explain the sextet).





Figure S20. Proposed biosynthetic precursors of irinan A (2), B (3) and the previously reported androwithanolide cinedione (8).



**Figure S21.** Intrinsic reactivity of 4β-hydroxywithanolide E (1) in oxidative conditions. Formation of irinan A (2) as judged by extracted ion chromatograms of m/z 315 [M + H – H<sub>2</sub>O]<sup>+</sup> in comparison to an authentic irinan A (2) reference.

**Table S1.** <sup>1</sup>H NMR data (CDCl<sub>3</sub>, 400 MHz, 298 K) of withanolide E (**4**), withanolide F (**5**) and perulactone H (**6**) in comparison with literature data (δ in ppm, *J* in Hz).

	28 21 0H 18 0H 18 0H 16 18 0H 16 Withanolide E (4)		23 23 21 0H 22 18 0H 20 16 16 16 16 17 Withanolide F (5)		OH: 28 O OH: 27 OH:	
Ato	<sup>1</sup> H	reference [1]	<sup>1</sup> H	reference [1]	<sup>1</sup> H	reference [1]
m				7.051.44	7.01.11.40.0	
H-2	6.03 dd	6.02 dd	5.86 dd	5.86 br dd	5.91 dd (9.9,	5.90 dd
11.2	(10.1, 2.9)	(10.1, 2.8)	(10.0, 2.0)	(9.9, 1.8)	2.1)	(9.9, 1.7)
H-3	6.81 ddd	6.81 ddd	6.76 ddd	6.76 ddd	6.79 ddd	6.79 ddd
	(10.2, 6.4, 2.4)	(10.1, 6.4, 2.8)	(10.0, 5.0, 2.5)	(9.9, 4.6, 2.3)	(10.1, 4.8, 2.5)	(9.9, 4.9, 2.3)
H-4	n.d. <sup>a</sup>	not reported	3. 27 br dd	3.27 br dd	3.30 br d	3.30 br dd
		1	(21.4, 1.7)	(21.1, 2.3)	(21.0)	(21.2, 2.3)
			2.83 dd	2.83 dd	2.86 dd	2.87 dd
			(21.1, 5.0)	(21.1, 4.6)	(21.2, 4.3)	(21.2, 4.9)
H-6	3.18 br s	3.18 br s	5.61 m	5.60 m	5.61 m	5.61 m
H-7	n.d. <sup>a</sup>	not reported	n.d. <sup>a</sup>	not reported	n.d. <sup>a</sup>	1.86-1.95 m
H-8	n.d. <sup>a</sup>	not reported	n.d. <sup>a</sup>	not reported	n.d. <sup>a</sup>	1.92 m
H-9	n.d. <sup>a</sup>	not reported	n.d. <sup>a</sup>	not reported	n.d. <sup>a</sup>	2.13 m
H-11	n.d. <sup>a</sup>	not reported	n.d. <sup>a</sup>	not reported	n.d. <sup>a</sup>	2.36 m, 1.65 m
H-12	n.d. <sup>a</sup>	not reported	n.d. <sup>a</sup>	not reported	n.d. <sup>a</sup>	2.34 m, 1.58 m
H-15	n.d. <sup>a</sup>	not reported	n.d. <sup>a</sup>	not reported	n.d. <sup>a</sup>	1.77 m, 1.62 m
H-16	n.d. <sup>a</sup>	not reported	n.d. a	not reported	n.d. <sup>a</sup>	2.63 ddd (15.2, 10.9, 1.7) 1.88 m
H-18	1.09 s	1.09 s	1.13 s	1.13 s	0.99 s	0.99 s
H-19	1.24 s	1.24 s	1.24 s	1.23 s	1.27 s	1.27 s
H-21	1.41 s	1.41 s	1.43 s	1.42 s	1.27 s	1.27 s
H-22	4.89 dd	4.89 dd	4.95 dd	4.94 dd	3.74 dd	3.74 d
11.00	(11.4, 4.8)	(11.5, 5.1)	(9.9, 6.6)	(9.4, 6.4)	(10.5, 2.1)	(10.3)
H-23	2.51 m	2.51 m	n.d. <sup>a</sup>	not reported	n.d. <sup>a</sup>	1.79 m, 1.62 m
H-24	-	-	-	-	n.d. <sup>a</sup>	2.78 m
H-25	1 00 ~	1 00 -	1 00 -	1 90 ~	n.d. <sup>a</sup>	2.68 m
H-27	1.88 s	1.88 s	1.89 s	1.89 s	1.20 d (7.6)	1.20 d (7.5)
H-28	1.94 s	1.94 s	1.95 s	1.94 s	4.48 dd	4.48 dd
					(9.2, 7.2)	(9.2, 7.2)
					4.11 dd (9.0, 8.4)	4.11 dd
					(2.0, 0.4)	(9.2, 9.2)

<sup>&</sup>lt;sup>a</sup> not determined using <sup>1</sup>H NMR data

## **Supporting references**

1. Ozawa, M.; Morita, M.; Hirai, G.; Tamura, S.; Kawai, M.; Tsuchiya, A.; Oonuma, K.; Maruoka, K.; Sodeoka, M. *ACS Med. Chem. Lett.* **2013**, *4*, 730–735.